U.S. markets open in 5 hours 46 minutes

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3400-0.0415 (-10.88%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.3815
Open0.3900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3358 - 0.4060
52 Week Range0.0940 - 0.4300
Volume2,261,583
Avg. Volume929,758
Market Cap123.562M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0920
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
    ACCESSWIRE

    Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios

    This Definitive Agreement is expected to generate an excess of $47,5M CAD in revenue for TetraOTTAWA, ON / ACCESSWIRE / May 5, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF)(FSE:JAM1), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.

  • Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
    ACCESSWIRE

    Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals

    A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary settingOTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce that it has received authorization from the Veterinary Drugs Directorate of Health Canada for a one year extension to continue the clinical trial evaluating the safety, tolerability and potential efficacy of its veterinary ophthalmic drug, PPP-003v, in the treatment of indolent corneal ulcers in companion animals.

  • Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
    ACCESSWIRE

    Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

    The addressable market in Canada is estimated to be $80M CDN by 2022.Tetra also applies for a Health Canada Cannabis Drug LicenseOTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc.